HOOKIPA Pharma (NASDAQ:HOOK) Bolsa

HOOKIPA PHARMA INC

HOOKIPA Pharma

HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.

HOOKIPA Pharma Inc

Hooker Furnishings Corporation - Common Stock

Hooker Furnishings Corp

<a href="https://www.globenewswire.com/Tracker?data=HMXwERE9PQskd73yKQRzMih2mDrTOTJc3AP_16WsqAFlMeJPPFgyAIBJX3VCN6_ztabx0RwDCPeoQVGtJtkOgq661KIk8QWPirFVAzu8o1hBSJH97uk1KOiYQIFgKlVKbEaDlFhV_XxCvAnkRvuaPkbNTlqegEvedh44GQ7FCyMWwqmv-bgTkc4JL2u14Snrub3Zv4007KtxIVphj9xMKg==">The poster</a> described an analysis of 40 cytokines, chemokines, soluble cell receptors, and growth factors (CCSGs) from plasma samples obtained prior to treatment from all patients enrolled in Actuate-1801 Part 3B. The analysis identified 7 biomarkers as uniquely significant predictors of favorable survival in the elraglusib-treated cohort, including one, CXCL2, with an inverse survival trend compared to the GnP control arm. This indicates that in patients not treated with elraglusib, high CXCL2 was unfavorable, but this trend is reversed with elraglusib treatment, highlighting the potential of elraglusib to favorably affect the immune microenvironment.

Biotech

News

General

ACTU

Actuate Therapeutics Highlights Biomarker, Machine Learning Data From Phase 2 Elraglusib Trial In First-Line Treatment Of  Metastatic Pancreatic Cancer

Wedbush analyst Daniel Ives reiterates Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Outperform and maintains $500 price target.

Price Target

Reiteration

Analyst Ratings

TSLA

Wedbush Reiterates Outperform on Tesla, Maintains $500 Price Target

You don't need to make reckless bets in the stock market or fall for scammy investment schemes to lose money. Sometimes, the biggest threats to your financial future are the quiet, unassuming habits that slowly drain your wealth in the background. They rarely make headlines, and they don't feel dramatic in the moment—but over time, they quietly erode your ability to build lasting security. These are the seven silent wealth drains that might already be working against you—and what to do about each one before they permanently set you back.
<h2 class="wp-block-heading">1. Lifestyle Creep</h2>
This one happens slowly, almost invisibly. You get a raise, and suddenly your $2,000 vacation becomes a $6,000 luxury escape. The sensible car you were perfectly happy with now feels "beneath you," and it gets swapped out for something flashier. The takeout orders increase, the impulse Amazon purchases multiply, and the monthly bills balloon—not because you needed more, but because you could afford more.
The problem? Every time your income rises and your spending rises with it, you&#8217;re robbing your future self of the opportunity to build wealth. That extra $10,000 a year could have gone into your IRA, into real estate, into a brokerage account compounding quietly for the next 30 years. Instead, it gets absorbed into an upgraded lifestyle that feels normal almost immediately—and hard to scale back.
The fix isn't deprivation—it's discipline. Lock in your lifestyle before the raise. If you get a $10,000 raise, try saving or investing at least $5,000 of it before you touch the rest. Future-you will thank you.
Related:
<ul class="wp-block-list">
<li>This Jeff Bezos-backed startup will allow you to <a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=byerscta100">become a landlord in just 10 minutes, with minimum investments as low as $100</a>.</li>
<li>Put your money to work for you: In terms of getting money back, <a href="https://www.gobankingrates.com/best-banks-c/">these bank accounts put traditional checking and savings accounts to shame</a>.</li>
</ul>
<h2 class="wp-block-heading">2. Subscription Sprawl</h2>
You probably don't even know how many subscriptions you're currently paying for. Between streaming services, news sites, productivity apps, forgotten software trials, and gym memberships that seemed like a good idea in January, these recurring charges are the financial equivalent of death by a thousand cuts. $9.99 here, $14.99 there—individually, they're harmless. Collectively, they're often hundreds, sometimes thousands of dollars a year.
What makes this so dangerous is how invisible it is. These aren't big, emotional purchases you consciously weigh—they're quiet, autopilot charges that keep hitting your credit card month after month. And every dollar wasted on a forgotten subscription is a dollar not earning compound returns somewhere else.
The solution? Set a calendar reminder every 3–6 months to audit your subscriptions. Open your bank and credit card statements, sort by recurring charges, and get ruthless. If it doesn't spark value, cut it. Let "set it and forget it" become "set it and review it."
<h2 class="wp-block-heading">3. High-Interest Debt</h2>
Credit card balances. Buy-now-pay-later loans. Personal loans with double-digit interest rates. These might feel manageable—just $3,000 or $4,000 spread across a couple of cards—but they're often doing more financial damage than you realize. With interest rates of 20% or more, even a modest balance can snowball into a mountain of debt that's hard to escape.
Here's the math: if you&#8217;re making the minimum payment on a $5,000 credit card at 20% interest, it can take over a decade to pay it off—and you'll likely pay more than double in total. That's money that could've been earning for you instead of bleeding out to lenders.
Before you even think about investing, attack your high-interest debt with laser focus. Every dollar you put toward it gives you a "return" equal to the interest rate you&#8217;re avoiding. Once it's paid off, redirect those payments toward long-term savings and investments.
<h2 class="wp-block-heading">4. Idle Cash</h2>
There's nothing wrong with keeping cash on hand—but too much of it sitting in the wrong place is quietly working against you. If you've got thousands languishing in a checking account earning 0.01% interest—or worse, under your mattress—it's not just doing nothing. It's actively losing value to inflation.
Inflation doesn't feel like a bill, but it functions like one. If inflation runs at 3% and your cash is earning 0.01%, your purchasing power is shrinking year after year. That emergency fund that felt solid five years ago may no longer cover the same expenses today.
A better approach is to segment your cash. Keep 3–6 months of essential expenses in a high-yield savings account or money market fund—somewhere safe, but with a real return. Everything beyond that should be working harder for you: invested in diversified assets that historically outpace inflation and help your money grow.
<h2 class="wp-block-heading">5. Fees You Don't See</h2>
You probably wouldn't knowingly pay $10,000 a year to someone just to manage your investments—but many people do exactly that without realizing it. Hidden fees in mutual funds, advisory charges, transaction costs, and seemingly harmless 1% management fees can quietly siphon six figures from your portfolio over time.
Let's break it down. A 1% annual fee on a $500,000 portfolio is $5,000 per year. Over 30 years, with compounding lost, that can easily cost you over $150,000. That's not pocket change—that's retirement years shaved off the back end.
What can you do? Start by getting clarity. Ask your advisor to spell out all fees in plain English. Use low-cost index funds or ETFs where possible, and favor platforms that minimize transaction and management fees. A few percentage points saved here and there can add up to serious money decades down the line.
Trending: 
<ul class="wp-block-list">
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/cancervax-advertorial-y2">Back a bold new approach to cancer treatment with high-growth potential.</a></li>
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/mode-mobile-accredited-investor-y2">invest with $1,000 at just $0.30/share.</a></li>
</ul>
<h2 class="wp-block-heading">6. Delayed Investing</h2>
There's always a reason to wait. The market feels uncertain. You don't have enough saved. You're still learning. But while you're on the sidelines, time keeps ticking—and that's the one resource you can't get back.
The reality is this: the earlier you start, the less you have to invest to reach the same goal. That's the magic of compounding. Delay by five years, and you may need to double your monthly contributions just to catch up. And let's be honest—no one ever feels fully "ready" to invest. There will always be a new headline, a looming recession, or a market dip to worry about.
Start small. Automate contributions. Let the habit build. Because in investing, time in the market always beats timing the market.
<h2 class="wp-block-heading">7. Ignoring Inflation</h2>
You might not see it, but inflation is constantly nibbling away at your purchasing power. The $1,000 you tuck under your mattress today will not buy $1,000 worth of goods a decade from now. Over 20–30 years, that erosion becomes dramatic—especially when you&#8217;re planning for retirement or other long-term goals.
A gallon of milk, a tank of gas, a doctor's visit—these things will cost more in the future. If your money isn't growing at least as fast as inflation, you're falling behind even if your balance stays the same.
The fix is planning with inflation in mind. Don't just look at nominal dollars—think about what those dollars will actually buy in the future. Prioritize investments like stocks, real estate, and Treasury Inflation-Protected Securities (TIPS) that tend to outpace inflation over time. Safe doesn't always mean smart when it comes to long-term wealth.
<h2 class="wp-block-heading">The Takeaway</h2>
You don't have to blow your money to lose it. These silent wealth drains work quietly, month after month, year after year. They don't grab your attention like a bad stock pick or a big splurge, but they do just as much damage—if not more—because they often go unnoticed until it's too late.
Wealth isn't just about what you earn—it's about what you keep, what you grow, and what you don't leak out the sides. Fixing these issues doesn't require genius or a windfall. It just takes awareness, a little strategy, and a willingness to plug the holes early.
Clean up the leaks. Redirect those dollars toward your future. Let your money do what it was always meant to do: build a life that feels free, secure, and fully yours.
See Next: 
<ul class="wp-block-list">
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=jeffbezos100"> Here&#8217;s how you can earn passive income with just $100.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://benzingapartners.go2cloud.org/aff_c?offer_id=532&amp;aff_id=1">you can become an investor for $0.80 per share today.</a></li>
</ul>
<h2 class="wp-block-heading">Want a Second Opinion on Your Finances?</h2>
If you're serious about plugging the leaks and building a more intentional financial future, <a href="https://www.rm2djk4ss.com/BW4BPX/J8P3N/">Wiser Advisor can help</a>. Its platform connects you with experienced, vetted fiduciary advisors who can break down your money situation, uncover the quiet drains you might be missing, and map out a smarter path forward for free.

Personal Finance

7 Silent Wealth Drains That Are Sabotaging Your Future

A popular crypto trader is raising concerns about the price stability of Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>), a popular meme coin rivaling Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>). 
The trader, known online as Altcoin Sherpa, <a href="https://x.com/AltcoinSherpa/status/1935699918649536605">shared </a>with his 248,000+ followers on X (formerly Twitter) that WIF must maintain a key support level of $0.78 or risk entering a prolonged downward trend.
"WIF needs to hold these levels or a broader decline may follow for similar tokens," he wrote, suggesting that many lower-timeframe charts already show bearish structures.
WIF is currently trading at $0.8001, up about 0.5% over the past 24 hours.
In a separate observation, Sherpa <a href="https://x.com/AltcoinSherpa/status/1935687524313391241">shared </a>a technical chart indicating that Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) could be preparing for a breakout toward an all-time high near $124,000. 
Despite prevailing economic uncertainty, he remains optimistic.
He pointed to ongoing geopolitical tensions and the lack of interest rate cuts, yet noted, "BTC is still above $100,000? That's bullish."
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46016723/mantles-tim-chen-explains-why-layer-2-ecosystems-are-critical-despite-retail-hesitation">Mantle&#8217;s Tim Chen Explains Why Layer 2 Ecosystems Are Critical Despite Retail Hesitation</a>
Still, he urged caution. 
A surprise event or unfavorable news could trigger a sharp drop below $100,000, he said. "I'm not jumping into many trades at the moment. I'm fine holding some losing positions for now. Better to be patient and use this time for research."
At the time of writing, Bitcoin was priced at $105,980, up about 1% for the day.
The trader also <a href="https://x.com/AltcoinSherpa/status/1935665703362932742">commented </a>on Hyperliquid (CRYPTO: HYPE), a newer layer-1 blockchain project. According to his analysis, the token may revisit support around $31.84 if Bitcoin experiences further volatility.
"HYPE might dip into the low $30s if BTC continues to trade sideways or declines. Still, it's one of the stronger performers this cycle, and I'm holding my staked position," he wrote.
HYPE was trading at $37.2 at the time of reporting, down over 3% in the past 24 hours.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46016990/apple-google-and-facebook-among-services-exposed-in-massive-leak-of-more-than-16-billion-login-records">Apple, Google and Facebook Among Services Exposed In Massive Leak of More Than 16 Billion Login Records</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$WIF

Trader Warns Dogwifhat Could Trigger Meme Coin Meltdown If Key Level Breaks

Wells Fargo analyst Derek Archila maintains aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) with a Overweight and raises the price target from $17 to $25.

ATYR

Wells Fargo Maintains Overweight on aTyr Pharma, Raises Price Target to $25

Wedbush analyst Jay McCanless maintains Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) with a Outperform and lowers the price target from $190 to $145.

BLDR

Wedbush Maintains Outperform on Builders FirstSource, Lowers Price Target to $145

Wells Fargo analyst Aaron Rakers maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Overweight and raises the price target from $130 to $150.

Wells Fargo Maintains Overweight on Micron Technology, Raises Price Target to $150

Wells Fargo analyst Steven Cahall maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Overweight and raises the price target from $1222 to $1500.

NFLX

Wells Fargo Maintains Overweight on Netflix, Raises Price Target to $1500

WIIM

CMCM

Cheetah Mobile shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

Politics

iShares MSCI Israel Capped Investable Market Index Fund

Israeli, Iranian Governments Both Report Iranian Missiles Fired Toward Israel

Macro Economic Events

Economics

Federal Reserve

Fed's Waller Says We Don't Want To Wait Until Job Market Tanks Before Cutting Rates

GPUS

Hyperscale Data shares are trading higher after the company announced its Bitnile.com said it accepts $TRUMP meme coin to its social casino games.

Wells Fargo analyst Elyse Greenspan maintains Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) with a Overweight and raises the price target from $328 to $333.

Wells Fargo Maintains Overweight on Progressive, Raises Price Target to $333

Wells Fargo analyst Christian Wetherbee maintains GXO Logistics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXO#NYSE">GXO</a>) with a Overweight and raises the price target from $44 to $48.

Wells Fargo Maintains Overweight on GXO Logistics, Raises Price Target to $48

Fed's Waller Says Tariffs Should Be A One Off Level Effect On And Not Persistent Boost To Inflation; Says Fed Has Been On Pause For Six Months Waiting For Inflation Shock

Fed's Waller Says Fed Is In A Position For Cuts As Early As July

DASH reverses early weakness at the time of alert
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/18204423/Screenshot-2025-06-18-at-4.39.07%E2%80%AFPM-1024x1021.png" alt="" class="wp-image-14601" /></figure>
DoorDash Inc. (DASH) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:02 AM on June 18th, a significant trading signal occurred for DoorDash Inc. (DASH) as it demonstrated a Power Inflow at a price of $216.06. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in DoorDash's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in DoorDash's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for DASH, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025</a>, which are responsible for parts of the data within this article.
After Market Close UPDATE:
The price at the time of the Power Inflow was $216.06. The returns on the High price ($221.31) and Close price ($220.59) after the Power Inflow are respectively 2.4% and 2.1%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Past performance is not indicative of future results

Equities

Technicals

Opinion

Signals

Trading Ideas

DASH

DoorDash Rises 2.4% After Key Trading Signal

Wells Fargo analyst Tiago Fauth maintains Verona Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) with a Overweight and raises the price target from $107 to $138.

VRNA

Wells Fargo Maintains Overweight on Verona Pharma, Raises Price Target to $138

LUCY

Innovative Eyewear shares are trading higher after the company announced a partnership with Smartech Retail Group to showcase the Reebok Powered by Lucyd collection and other brands at the new Smartech location in New York City.

MITQ

Moving iMage Technologies shares are trading higher after the company announced a $9 million contract with a national cinema exhibition customer regarding the sale and installation of 150 Barco laser projections along with a range of MIT-manufactured equipment.

Press Releases

Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm

HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

Health Care

HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024

HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker

Earnings

HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV

Comments

HOOKIPA Pharma

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL